{
  "item1": "leading provider health science solutions, technologies, expertise services deliver complete workflows discovery development, diagnosis cure. Revvity revolutionizing what’s possible healthcare, specialized focus areas translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection diagnosis, informatics more. headquarters Waltham, Massachusetts, market products services more than 160 countries. December 29, 2024, employed approximately 11,000 employees.",
  "item7": "Fiscal Year 2024 Compared Fiscal Year 2023 Revenue fiscal year 2024 $1,500.9 million, compared $1,458.2 million fiscal year 2023, increase $42.7 million, 3%, which includes approximate 1% decrease revenue attributable unfavorable changes foreign exchange rates. T Diagnostics segment revenue during fiscal year 2024 due increase $43.7 million immunodiagnostics revenue increase $22.6 million reproductive health revenue, partially offset decrease $23.7 million applied genomics revenue. Segment operating income fiscal year 2024 $372.4 million, compared $320.1 million fiscal year 2023, increase $52.3 million, 16%. Segment operating margin increased 286 basis points fiscal year 2024, compared fiscal year 2023, primarily due olume, productivity initiatives, cost containment.",
  "item2": "Management’s Discussion Analysis Financial Condition Results Operations leading provider health science solutions, technologies, expertise services deliver complete workflows discovery development, diagnosis cure. Revvity revolutionizing what’s possible healthcare, specialized focus areas translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection diagnosis, informatics more. principal products services two reportable segments are: . Provides products services targeted towards life sciences customers."
}